Stroke secondary prevention and blood pressure reduction: An observational study of the use of PROGRESS therapy

Fundamental and Clinical Pharmacology

Volumn 22, Issue 2, 2008, Pages 217-222

  Bugnicourt, Jean Marc ^a   Chillon, Jean Marc ^b,c   Canaple, Sandrine ^a   Lamy, Chantal ^a   Godefroy, Olivier ^a  

^a Amiens University Medical Center and Jules Verne University of Picardy   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Anti hypertensive therapy; Brain infarction; Intracranial haemorrhage; Perindopril; Stroke prevention

Indexed keywords

INDAPAMIDE; PERINDOPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN INFARCTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COUGHING; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTITIONER; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; ORTHOSTATIC HYPOTENSION; PATIENT INFORMATION; PRIORITY JOURNAL; SECONDARY PREVENTION; SUSTAINED DRUG RELEASE; TRANSIENT ISCHEMIC ATTACK;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DELAYED-ACTION PREPARATIONS; DIURETICS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; HYPERTENSION; INDAPAMIDE; INTERVIEWS AS TOPIC; ISCHEMIC ATTACK, TRANSIENT; MALE; PERINDOPRIL; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; STROKE;

EID: 40949157613     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00570.x     Document Type: Article

References (23)

1. Goldstein L.B., Hey L.A., Laney R. North Carolina stroke prevention and treatment facilities survey. Stroke (2000) 31 66 70.
2. Kernan W.N., Viscoli C.M., Brass L.M., Makuch R.W., Sarrel P.M., Horrowitz R.I. Blood pressure exceeding national guidelines among women after first stroke. Stroke (2000) 31 415 419.
3. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. J. Hypertens. (1996) 14 (Suppl. 2) S41 S46.
4. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaaaaemic attack. Lancet (2001) 358 1033 1041.
5. PROGRESS Management Committee. PROGRESS: characteristics of the study population at baseline. J. Hypertens. (1999) 17 1647 1655.
6. PATS Collaborating group. Post-stroke antihypertensive treatment study: a preliminary result. Chinese Med. J. (1995) 108 710 717.
7. Adams H.P., Jr., Bendixen B.H., Kappelle L.J. et al. Classification of subtype of acute ischaemic stroke. Definitions for use in a Multicenter Clinical Trial. Stroke (1993) 24 35 41.
8. Rankin J. Cerebral vascular accidents in patients over the age of 60: prognosis. Scott. Med. J. (1957) 2 200 215.
9. Sacco R.L., Adams R., Albers G. et al. Guidelines for prevention of stroke in patients with ischaemic stroke or transient ischaemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke, co-sponsored by the Council on Cardiovascular Radiology and Intervention. Stroke (2006) 37 577 617.
10. Coull A.J., Lovett J.K., Rothwell P.M. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ (2004) 328 326.
11. Chapman N., Huxley R., Anderson C. et al. Writing Committee for the PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke (2004) 35 116 121.
12. Hisatomi A., Robert G.H., Colman S. et al. for the PROGRESS Collaborative Group. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischaemic attack. Stroke (2005) 36 2164 2169.
13. Naess H., Waje-Andreassen U., Thomassen L., Nyland H., Myhr K.M. Do all young ischaemic stroke patients need long-term secondary preventive medication? Neurology (2005) 65 609 611.
14. Langhorne P., Dennis M. Stroke units: an evidence based approach. BMJ Books, London, 1998, p. 112
15. Indredavik B., Bakke F., Slordahl S.A., Rokseth R., Haheim L.L. Stroke unit treatment: 10-year follow-up. Stroke (1999) 30 1524 1527.
16. Sappok T., Faulstich A., Stuckert E., Kruch H., Marx P., Koennecke H.O. Compliance with secondary prevention of ischaemic stroke: a prospective evaluation. Stroke (2001) 32 1884 1889.
17. Hillen T., Dundas R., Lawrence E., Stewart J.A., Rudd A.G., Wolfe C.O. Antithrombotic and antihypertensive management 3 months after ischaemic stroke: a prospective study in an inner city population. Stroke (2000) 31 469 475.
18. Amarenco P., Bogousslavsky J., Callahan A., III., et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. (2006) 355 549 559.
19. McColl A., Smith H., White P., Field J. General practitioners' perceptions of the route to evidence based medicine: a questionnaire survey. BMJ (1998) 316 361 365.
20. Holloway R.G., Benesch C., Rush S.R. Stroke prevention: narrowing the evidence-practice gap. Neurology (2000) 54 1899 1906.
21. Dahlöf B. Prevention of stroke in patients with hypertension. Am. J. Cardiol. (2007) 100 (suppl) 17J 24J.
22. Teo K., Yusuf S., Sleight P. et al. for the ONTARGET/TRANSCEND Investigators. Rationale design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am. Heart J. (2004) 148 52 61.
23. Diener H.C., Sacco R., Yusuf S. Steering Committee; PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc. Dis. (2007) 23 368 380.